Attendee search 

Clinical stage biotech with a solution for gene/protein delviery to cancer cells.

Tocagen is a private biopharma developing a unique retroviral replicating vector (RRV) platform that can efficiently delivery a gene or protein of choice selectively to cancer cells.

·         A fundamental challenge in oncology is to selectively deliver active agents to cancer cells while sparing healthy tissue.  We believe we may have found a solution.
·         Unlike oncolytic viruses, RRVs are unique because they replicate by budding-off from the host cancer cell which allows "stealth" spread through cancer tissue without being cleared by the immune system.
·         Our RRV system is capable of delivering genes such as those that code for prodrug activator enzymes, shRNA, or therapeutic proteins.
·         Our lead RRV product candidate, Toca 511, delivers a prodrug activator gene, cytosine deaminase (CD), selectively to cancer cells.
·         Toca 511 is used in combination with Toca FC, a proprietary formulation of 5-FC, that is converted in the presence of CD in infected cancer cells to 5-FU.
·         To date, Toca 511 & 5-FC has been dosed in 36 patients with high grade glioma in two ascending dose Phase I trials.
·         In addition to a promising safety and efficacy profile in patients, we have also accumulated data in patients supporting the anticipated mechanism of action for this approach
·         Now that we have clinical validation for our technology platform, we are interested in partnership discussions e.g. building new RRV constructs for the delivery of a gene or protein of interest to the partner.

More details about our technology can be found at www.tocagen.com and more information about our clinical trials can be found here: http://clinicaltrials.gov/ct2/results?term=tocagen

Mallinckrodt, the pharmaceuticals business of Covidien, is a vertically integrated leader in providing products used in diagnostic procedures and in the treatment of pain and related conditions.  Covidien announced last December that they are spinning off Mallinckrodt into a stand-alone company, a process that is expected to be completed in mid-2013.  Mallinckrodt is the largest US supplier, by prescription, of opioid pain medications and a leading manufacturer of active pharmaceutical ingredients. It is also the largest US supplier of the medical isotope technetium-99m and an industry leader in radiopharmaceuticals and contrast media and delivery systems.  Sales in 2011 were $2.0 billion. Please visit www. mallinckrodt.com to learn more about our business.  The company’s branded pharmaceuticals portfolio includes EXALGO® (hydromorphone HCl) Extended-Release Tablets (CII) and PENNSAID® (diclofenac sodium topical solution) 1.5% w/w.  In June 2012, Mallinckrodt entered into agreements with Horizon Pharma and Zogenix Inc. to co-promote their branded pharmaceuticals for rheumatoid arthritis and acute migraine, respectively.  In August 2012, the FDA approved the 32 mg tablet strength of EXALGO® (hydromorphone HCI) Extended-Release Tablets (CII).  Mallinckrodt is primarily pursuing acquisition or licensing deals for pharmaceuticals which are either in late stage development or are approved for commercialization.

Our strategy is to selectively collaborate with leading companies with the resources and capabilities to assist us in developing and commercializing some of our product candidates, particularly in target indications for which our collaborator has significant expertise or that involve large primary care markets. We generally seek co-promotion or co-commercialization rights in alliances.

We have a collaboration with AstraZeneca focused in cognitive disorders that includes AZD-3480 and AZD-1446.  We have the option to co-promote  certain compounds licensed under our cognitive disorders agreement to selected specialist physicians in the US.

 We are currently interested in exploring alliances or collaborations for:

• TC-5619, which is in on-going Phase 2 trials in negative symptoms of schizophrenia and ADHD predominantly inattentive subtype; • TC-6499, which in a Phase 2a study showed encouraging potential to enhance GI motility relevant to treating GI/GU disorders such as diabetic gastroparesis and IBS-C/CIC; and • Targacept’s Parkinson’s disease/levodopa-induced dyskinesia program to exploit NNR Therapeutics for symptomatic treatment and disease modification.

We are receptive to evaluating clinical-stage CNS, GI/GU or Orphan opportunities to complement our pipeline.

Quintiles is the only fully integrated biopharmaceutical services provider offering clinical, commercial consulting and capital solutions worldwide.  We help customers manage change, navigate risk and seize opportunities.  Quintiles has helped develop or commercialize all of the top 50 best-selling drugs.  Our more than 24,000 employees in nearly 60 countries deliver on promises to customers with an unwavering commitment to patients, safety and ethics.

Late stage specialty CNS pharmaceutical company with neurology and psych assets looking for partnerships for in and out license.

HealthCare Royalty Partners is a global healthcare investment firm with $1.5 billion in assets under management. Launched in 2007 by Founding Managing Directors Gregory B. Brown, M.D., Todd C. Davis and Clarke B. Futch, HC Royalty specializes in making structured investments in commercial-stage healthcare companies and products. Our deep experience, broad and flexible investment platform and proven track record set HC Royalty apart from other firms.

We closed on our first fund, HealthCare Royalty Partners, L.P., in July 2008 with over $500 million in capital. At closing this represented one of the largest inaugural healthcare-focused funds ever raised. In December 2011, we closed the largest private equity fund dedicated to healthcare royalty investments, HealthCare Royalty Partners II, L.P. and an affiliated fund, with $1 billion in capital. Our world-class list of investors consists of public and corporate pension funds, financial institutions, insurance companies, funds-of-funds and university endowments.

Our broad-based internal team has deep investment skills, as well as financial, legal and operational expertise. Collectively, these individuals possess over 100 years of healthcare and financial experience specifically in principal investing, structured finance, healthcare industry senior management, Wall Street research, healthcare industry consulting, and scientific and clinical advisory work